Navigation Links
Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease
Date:12/3/2010

PALO ALTO, Calif., Dec. 3, 2010 /PRNewswire/ -- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.  Of the 500,000-1.5 million Parkinson's patients in the United States, about 50% experience incidence of levodopa-induced dyskinesias (LIDs), for which there are no approved treatments.  NP002 is a small molecule, orally available nicotinic receptor agonist that has been shown in preclinical studies to reduce LIDs without affecting Parkinsonian symptoms.

A double blinded, placebo controlled, Phase 1/2 study was performed to assess the safety and tolerability of NP002 in a total of 65 individuals with Parkinson's disease and documented LIDs.  The primary objective of the study was the establishment of safety and tolerability of NP002, with patients being assessed over a 14-week treatment and monitoring period.  The secondary objective was to investigate the effects of NP002 on a set of Parkinson's disease and dyskinesia assessment scales, including The Unified Parkinson's Disease Rating Scale (UPDRS), the Unified Dyskinesia Rating Scale (UDRS), the Lang-Fahn Activities of Daily Living Scale (LF-ADL), and the clinician and patient global impressions of change scales (CGIC and PGIC).

NP002 administered concurrently with levodopa treatment was found to be generally safe and well-tolerated in Parkinson's patients with LIDs.  In addition, NP002 was not associated with any impulsivity or withdrawal issues when compared to placebo.  Although the trial was not powered as an efficacy study, clinically relevant trends and, in two cas
'/>"/>

SOURCE Neuraltus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
2. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
3. Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection
4. Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP
5. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
6. Onyx Pharmaceuticals Announces December 2010 Investor Events
7. Endo Pharmaceuticals Holdings Inc. Announces Pricing of Private Offering of Senior Notes
8. Prolong Pharmaceuticals Boosts Executive Team
9. Prism Pharmaceuticals Receives FDA Approval of Ready-to-Use NEXTERONE® (amiodarone HCl) Premixed Injection
10. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
11. Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provids Unique MS Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... FAIRFIELD, N.J. , July 30, 2015 /PRNewswire/ ... Ferrer, completed the second Phase III clinical study ... development for impetigo.  Medimetriks owns the exclusive U.S. ... The global trial, conducted at 44 centers with ... and pediatric patients aged 2 months and older ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... ... services, announced today that the latest issue of Inclusive™ magazine, its multimedia publication ... platforms. The digital edition of the new issue, Volume 6, Issue 2, as ...
(Date:7/30/2015)... ... 2015 , ... Western University of Health Sciences faculty, students and alumni were ... largest sports and humanitarian event in the world this year and the single biggest ... July 25 through August 2, 2015, benefited from the participation of WesternU’s colleges of ...
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd ... in taxpayer money to fund the state’s large prison system, which has amassed largely ... highest rates of incarceration. In light of President Obama’s recent reduction of non violent ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer ... treatment designed specifically for the elimination of excess tissue under the chin, referred ... the state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex ... and surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a ... with many patients from around the world. , “Like treatment of any other disease ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... Center in Philadelphia have found that a signaling protein ... turned on in nearly all recurrent prostate cancers that ... up, the protein, called Stat5, may be a specific ... addition, the researchers, led by Marja Nevalainen, M.D., Ph.D., ...
... and use caution when exiting transportation , , SUNDAY, Dec. 30 ... slush and ice of winter requires special walking tactics, health ... careful, particularly since we haven,t had this type of weather ... specialist at Mount Sinai,s Department of Orthopaedics in New York ...
... injuries can happen to kids if precautions are skipped, ... Winter sports provide kids with great exercise and fun, ... say pediatric trauma experts. , "We see a startling ... snowmobile crashes and beyond," Amy Teddy, manager of the ...
... to make a different kind of New Year,s resolution, ... America,s Blood Centers and blood transfusion recipients across,the country ... National Blood Donor Month., Each year, more than ... to a recent study by W. Riley (et al) ...
... Dec. 28 Grubb & Ellis,Healthcare REIT, Inc. has ... closed on December 21, 2007., Park Place Office ... 133,000 square feet on eight and a half,acres in ... constructed in 1987,1988, and 2002, respectively, and offer tenants ...
... 500 Jobs, HARRISBURG, Pa., Dec. 28 A ... of the Butler,Memorial Hospital that will include a new ... the Department of Community and,Economic Development announced today. The ... The state,s aid will come in the form ...
Cached Medicine News:Health News:Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer 2Health News:Put Safety First During Winter Fun 2Health News:America's Blood Centers Thanks Donors During Celebration of National Blood Donor Month 2Health News:America's Blood Centers Thanks Donors During Celebration of National Blood Donor Month 3Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 2Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 3Health News:Pennsylvania Invests $13.4 Million to Kick Off Butler Memorial Hospital Expansion 2
Inquire...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: